Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Resonate Blends, Inc. (KOAN)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
26565 Agoura Road 91302
North Bergen, CA, US
North Bergen, CA, US
CEO
James W. Zimbler
Website
apollobiowellness.com
IPO
1993-03-31
CIK 897078 ISIN US76090M1027
Description
APOLLO BioWellness Inc. focuses its efforts on researching, formulating, and bringing to market products designed for human health within the regenerative medicine sector. A significant part of its operations involves the commercialization of licensed, naturally derived compounds currently awaiting patent approval, which are specifically engineered to boost an individual's innate capacity to mobilize adult stem cells from their own bone marrow. Additionally, the firm possesses the marketing rights for an all-natural, two-pronged dietary supplement crafted to help regulate hunger by engaging the body's intrinsic signaling pathways between the brain and the digestive system. Beyond its current offerings, the company is also deeply involved in research and development initiatives. These efforts are dedicated to exploring new frontiers, such as Secretogues aimed at enhancing a person's endogenous growth hormone synthesis, along with other natural bioactive formulations intended to optimize human physiological performance. This is achieved by harnessing the body's own biological mechanisms, entirely without the use of pharmaceutical drugs. The company maintains its corporate headquarters in North Bergen, New Jersey.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
5M
Beta
3.56
Float Shares
190.05M
Free Float %
97.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +20.00% | +33.33% | -33.33% | -29.41% | -78.18% | -60.85% | +33.33% | -98.00% | -99.76% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-20.84
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-10.2% Q1'26: -43.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+53.9% ★ Q1'26: +100.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-96.6% Q1'26: -124.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-57.6% Q1'26: -113.3% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-174.5% Q1'26: -1,484.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+109.5% Q1'26: +88.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-5.40× Q1'26: -5.39× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-1.60M
OE per share TTM
-0.01
Owner's Yield
-471.14%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
2.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
12
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 82-1042853 | 128.86M | 5.29% | 128.86M | — | 128.86M | — | OO | New York | 2018-01-02 | ↗ |
| 2 | AJB Capital Investments LLC | 5.57M | 7.40% | 5.57M | — | 5.57M | — | OO | United States | 2023-03-20 | ↗ |
| 3 | AJB Capital Managers LLC | 5.57M | 7.40% | 5.57M | — | 5.57M | — | OO | United States | 2023-03-20 | ↗ |
| 4 | Hoge | 5.20M | 12.57% | 5.20M | — | 5.20M | — | IN | United States | 2021-06-25 | ↗ |
| 5 | GS Capital Partners, LLC | 5.08M | 7.27% | 5.08M | — | 5.08M | — | OO | New York | 2022-07-20 | ↗ |
| 6 | I.R.S. Identification Nos. of above persons (entities only). | 3.52M | 5.06% | 3.52M | — | 3.52M | — | PN | Delaware, United States | 2022-07-27 | ↗ |
| 7 | Gregory O. Sargent | 1.15M | 39.99% | — | — | — | — | IN | : | 2006-12-21 | ↗ |
| 8 | ###-##-####) | 447.9K | 9.15% | — | — | 447.9K | — | IN | United States of America | 1996-02-12 | ↗ |
| 9 | 04-2507163) | 447.9K | 9.15% | — | — | 447.9K | — | HC | Commonwealth of Massachusetts | 1996-02-12 | ↗ |
| 10 | 94-3132809 | 225.0K | 4.60% | 200.0K | — | 225.0K | — | IA, PN | RCM General Corporation - CA Corporation | 1996-02-06 | ↗ |
| 11 | Paloma International L.P. | 130.7K | 4.90% | — | 130.7K | — | 130.7K | PN | Delaware | 2003-12-09 | ↗ |
| 12 | S. Donald Sussman | 130.7K | 4.90% | — | 130.7K | — | 130.7K | IN | United States | 2003-12-09 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
2.15M
Cash buys
—
Cash sales
—
Net activity
-2,150,638
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-03-08 | Hoge Richard | 10% Owner | — | D | Convertible Loan | 2,150,638 | 0.10 | 215.1K | 0 | — | ↗ |
| 2019-12-09 | Hoge Richard | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,000,000 | — | ↗ |
| 2019-10-25 | Selzer Geoffrey | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 1,053,312 | — | ↗ |
| 2019-10-25 | Kerwin Pamela | Officer | — | D | Common Stock | 0 | 0.00 | — | 124,228 | — | ↗ |
| 2019-03-25 | Asefi Wais | Director / Officer / 10% Owner | A-Award | A | Common Stock | 2,500,000 | 0.00 | — | 2,755,029 | — | ↗ |
| 2018-02-23 | Asefi Wais | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 1,211,777 | 0.00 | 121.18 | 3,816,653 | — | ↗ |
| 2017-05-09 | Asefi Wais | Director / Officer / 10% Owner | C-Conversion | A | Series C Preferred Stock | 2,000,000 | 0.00 | — | 2,000,000 | — | ↗ |
| 2017-01-01 | Thielen David Thomas | Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,500,000 | — | ↗ |
| 2017-01-01 | Miniello Nick Allen | Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,500,000 | — | ↗ |
| 2015-12-31 | Asefi Wais | Director / Officer / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-03-10 | Asefi Wais | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 65,640,207 | — | ↗ |
| 2007-05-16 | Deerwester Steven Richard | Officer | — | D | Incentive Stock Option (right to buy) | 10,000 | 1.98 | 19.8K | 0 | — | ↗ |
| 2007-05-03 | VITALE JUDITH A | Director | J-Other | A | Common Stock, no par value | 4,608 | 2.17 | 10.0K | 4,611 | — | ↗ |
| 2007-05-03 | STERLING JOHN M III | Director | — | D | Common Stock, no par value | 0 | 0.00 | — | 4,608 | — | ↗ |
| 2007-05-03 | SPENCER JOHN N JR | Director | J-Other | A | Common Stock, no par value | 4,608 | 2.17 | 10.0K | 24,766 | — | ↗ |
| 2007-05-03 | Mosley I Sigmund | Director | J-Other | A | Common Stock, no par value | 4,608 | 2.17 | 10.0K | 15,456 | — | ↗ |
| 2007-05-03 | BABB ROGER A | Director | J-Other | A | Common Stock, no par value | 4,608 | 2.17 | 10.0K | 52,782 | — | ↗ |
| 2006-12-21 | sargent gregory oliver | 10% Owner | — | D | Common Stock, no par value per share | 0 | 0.00 | — | 1,146,906 | — | ↗ |
| 2006-12-04 | SPENCER JOHN N JR | Director | J-Other | A | Common Stock, no par value | 3,984 | 2.30 | 9.2K | 20,158 | — | ↗ |
| 2006-11-03 | Deerwester Steven Richard | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2006-10-25 | SPENCER JOHN N JR | Director | J-Other | A | Non-Qualified Stock Option (right to buy) | 25,000 | 2.18 | 54.5K | 25,000 | — | ↗ |
| 2006-10-25 | Mosley I Sigmund | Director | J-Other | A | Non-Qualified Stock Option (right to buy) | 25,000 | 2.18 | 54.5K | 25,000 | — | ↗ |
| 2006-10-25 | BABB ROGER A | Director | J-Other | A | Non-Qualified Stock Option (right to buy) | 25,000 | 2.18 | 54.5K | 25,000 | — | ↗ |
| 2006-07-18 | Deerwester Steven Richard | Officer | J-Other | A | Incentive Stock Option (right to buy) | 10,000 | 2.16 | 21.6K | 10,000 | — | ↗ |
| 2006-06-07 | SPENCER JOHN N JR | Director | J-Other | A | Common Stock, no par value | 5,000 | 2.00 | 10.0K | 16,174 | — | ↗ |
| 2006-06-07 | Mosley I Sigmund | Director | J-Other | A | Common Stock, no par value. | 5,000 | 2.00 | 10.0K | 5,000 | — | ↗ |
| 2006-06-07 | Kane David G | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2006-06-07 | BABB ROGER A | Director | J-Other | A | Common Stock, no par value. | 5,000 | 2.00 | 10.0K | 5,000 | — | ↗ |
| 2006-06-01 | Mosley I Sigmund | Director | — | D | Non-Qualified Stock Option (right to buy) | 7,500 | 1.71 | 12.8K | 0 | — | ↗ |
| 2006-05-16 | Deerwester Steven Richard | Officer | J-Other | A | Incentive Stock Option (right to buy) | 10,000 | 1.98 | 19.8K | 10,000 | — | ↗ |
| 2006-03-16 | BABB ROGER A | Director | J-Other | D | Non-Qualified Stock option (right to buy) | 1,667 | 1.32 | 2.2K | 10,001 | — | ↗ |
| 2006-02-10 | Kane David G | Officer | J-Other | D | Incentive Stock Option (right to buy) | 2,500 | 1.71 | 4.3K | 0 | — | ↗ |
| 2005-12-09 | BROCK RICHARD T | Director / Officer / 10% Owner | S-Sale | D | Common Stock, no par value | 19,500 | 2.00 | 39.0K | 145,108 | — | ↗ |
| 2005-11-21 | BROCK RICHARD T | Director / Officer / 10% Owner | S-Sale | D | Common Stock, no par value | 34,000 | 2.73 | 92.7K | 164,608 | — | ↗ |
| 2005-10-21 | VITALE JUDITH A | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2005-10-13 | SPENCER JOHN N JR | Director | J-Other | A | Non-Qualified Stock Option (right to buy) | 25,000 | 1.47 | 36.8K | 25,000 | — | ↗ |
| 2005-10-13 | Mosley I Sigmund | Director | J-Other | A | Non-Qualified Stock Option (right to buy) | 25,000 | 1.47 | 36.8K | 25,000 | — | ↗ |
| 2005-10-13 | Kane David G | — | — | D | Incentive Stock Options | 10,000 | 1.47 | 14.7K | 0 | — | ↗ |
| 2005-10-13 | BROCK RICHARD T | Director / Officer / 10% Owner | J-Other | A | Non-Qualified Stock Option (right to buy) | 25,000 | 1.47 | 36.8K | 25,000 | — | ↗ |
| 2005-10-13 | BABB ROGER A | Director | J-Other | A | Non-Qualified Stock Option (right to buy) | 25,000 | 1.47 | 36.8K | 25,000 | — | ↗ |
| 2005-09-29 | LONGORIA JEFFREY | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2005-06-02 | ROTHENBERG ALAN I | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2005-06-02 | Kane David G | — | — | D | Incentive Stock Option | 2,500 | 1.71 | 4.3K | 0 | — | ↗ |
| 2005-06-02 | DOOLEY VINCENT J | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2005-05-31 | SPENCER JOHN N JR | Director | J-Other | A | Common Stock, no par value | 5,848 | 1.71 | 10.0K | 11,174 | — | ↗ |
| 2005-05-31 | Mosley I Sigmund | Director | J-Other | A | Common Stock, no par value | 5,848 | 1.71 | 10.0K | 5,848 | — | ↗ |
| 2005-05-31 | BABB ROGER A | Director | J-Other | A | Common Stock, no par value | 5,848 | 1.71 | 10.0K | 16,507 | — | ↗ |
| 2005-03-28 | SIMMONS DAVID R | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2005-02-20 | DOOLEY VINCENT J | Director | — | D | Non-Qualified Stock Option (right to buy) | 7,500 | 5.59 | 41.9K | 0 | — | ↗ |
| 2005-01-03 | LONGORIA JOSEPH | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2004-11-17 | SPENCER JOHN N JR | Director | — | D | Non-Qualified Stock Option (right to buy) | 7,500 | 5.50 | 41.3K | 0 | — | ↗ |
| 2004-06-23 | VITALE JUDITH A | Officer | A-Award | A | Incentive Stock Option (right to buy) | 6,000 | 2.45 | 14.7K | 6,000 | — | ↗ |
| 2004-06-23 | SIMMONS DAVID R | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 12,000 | 2.45 | 29.4K | 12,000 | — | ↗ |
| 2004-06-23 | LONGORIA JOSEPH | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 6,000 | 2.45 | 14.7K | 6,000 | — | ↗ |
| 2004-06-23 | LONGORIA JEFFREY | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 6,000 | 2.45 | 14.7K | 6,000 | — | ↗ |
| 2004-06-17 | SIMMONS DAVID R | Officer | P-Purchase | A | Convertible Preferred - Series D | 300 | 3.00 | 900.00 | 300 | — | ↗ |
| 2004-06-04 | BROCK RICHARD T | Director / Officer / 10% Owner | A-Award | A | Non-Qualified Stock Option (right to buy) | 85,216 | 2.84 | 242.0K | 85,216 | — | ↗ |
| 2004-05-07 | SPENCER JOHN N JR | Director | J-Other | A | Common Stock, no par value | 4,464 | 2.24 | 10.0K | 5,326 | — | ↗ |
| 2004-05-07 | ROTHENBERG ALAN I | Director | J-Other | A | Common Stock, no par value | 4,464 | 2.24 | 10.0K | 7,325 | — | ↗ |
| 2004-05-07 | KEANE JOHN F | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2004-05-07 | DOOLEY VINCENT J | Director | J-Other | A | Common Stock, no par value | 4,464 | 2.24 | 10.0K | 4,836 | — | ↗ |
| 2004-05-07 | BABB ROGER A | Director | J-Other | A | Common Stock, no par value | 4,464 | 2.24 | 10.0K | 10,659 | — | ↗ |
| 2004-02-24 | VITALE JUDITH A | Officer | A-Award | A | Incentive Stock Option (right to buy) | 30,000 | 5.37 | 161.1K | 30,000 | — | ↗ |
| 2004-02-24 | SIMMONS DAVID R | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 26,250 | 5.37 | 141.0K | 26,250 | — | ↗ |
| 2004-02-24 | LONGORIA JOSEPH | Officer | A-Award | A | Incentive Stock Option (right to buy) | 30,000 | 5.37 | 161.1K | 30,000 | — | ↗ |
| 2004-02-24 | LONGORIA JEFFREY | Officer | A-Award | A | Incentive Stock Option (right to buy) | 30,000 | 5.37 | 161.1K | 30,000 | — | ↗ |
| 2004-02-20 | DOOLEY VINCENT J | Director | — | D | Common Stock, no par value | 0 | 0.00 | — | 372 | — | ↗ |
| 2003-12-19 | JACKSON RICHARD D | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-11-17 | SPENCER JOHN N JR | Director | — | D | Common Stock, no par value | 0 | 0.00 | — | 862 | — | ↗ |
| 2003-09-29 | CALFEE MARSHA K | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-07-31 | VITALE JUDITH A | Officer | A-Award | A | Incentive Stock Option (right to buy) | 10,000 | 7.70 | 77.0K | 10,000 | — | ↗ |
| 2003-07-31 | SIMMONS DAVID R | Officer | A-Award | A | Incentive Stock Option (right to buy) | 3,190 | 7.70 | 24.6K | 3,190 | — | ↗ |
| 2003-07-31 | LONGORIA JOSEPH | Officer | A-Award | A | Incentive Stock Option (right to buy) | 10,000 | 7.70 | 77.0K | 10,000 | — | ↗ |
| 2003-07-31 | LONGORIA JEFFREY | Officer | A-Award | A | Incentive Stock Option (right to buy) | 10,000 | 7.70 | 77.0K | 10,000 | — | ↗ |
| 2003-07-31 | BROCK RICHARD T | Director / Officer / 10% Owner | A-Award | A | Incentive Stock Option (right to buy) | 10,000 | 7.70 | 77.0K | 10,000 | — | ↗ |
| 2003-07-07 | ROTHENBURG ALAN I | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-07-07 | KEANE JOHN F | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-07-07 | BOBB ROGER A | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-05-01 | JACKSON RICHARD D | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 7,500 | 12.04 | 90.3K | 7,500 | — | ↗ |
| 2003-01-21 | BROCK RICHARD T | Director / Officer / 10% Owner | A-Award | A | Non-Qualified Stock Option (right to buy) | 7,000 | 16.50 | 115.5K | 7,000 | — | ↗ |
| 2002-09-20 | BROCK RICHARD T | Director / Officer / 10% Owner | A-Award | A | Non-Qualified Stock Option (right to buy) | 6,667 | 7.71 | 51.4K | 6,667 | — | ↗ |
| 2001-05-14 | BROCK RICHARD T | Director / Officer / 10% Owner | A-Award | A | Non-Qualified Stock Option (right to buy) | 2,417 | 1.51 | 3.6K | 2,417 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-163.4K
Shares Outstanding
195.25M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2003 | David R. Simmons President and COO | 240.6K | — | — | 57.0K | — | 3.6K | 301.2K | 18.92% | ↗ |
| 2 | 2003 | Richard T. Brock Chairman and CEO | 270.0K | — | — | 17.0K | — | 4.2K | 291.2K | 5.84% | ↗ |
| 3 | 2003 | Joseph L. Longoria Sr. VP of Development & Services | 125.0K | 109.6K | — | 25.0K | — | — | 259.6K | 9.63% | ↗ |
| 4 | 2003 | Jeffrey L. Longoria Sr. VP of Sales | 125.0K | 98.0K | — | 25.0K | — | — | 248.0K | 10.08% | ↗ |
| 5 | 2003 | Judith A. Vitale CFO | 180.0K | — | — | 15.0K | — | 3.6K | 198.6K | 7.55% | ↗ |
| 6 | 2002 | Richard T. Brock Chairman and CEO | 250.0K | 235.0K | — | 13.3K | — | 3.4K | 501.8K | 2.66% | ↗ |
| 7 | 2002 | Judith A. Vitale CFO | 170.0K | 64.6K | — | 12.0K | — | 48.6K | 295.3K | 4.06% | ↗ |
| 8 | 2002 | David R. Simmons President and COO | 46.2K | 10.0K | — | 25.0K | — | 263.00 | 81.4K | 30.70% | ↗ |
| 9 | 2001 | Richard T. Brock Chairman and CEO | 240.0K | — | — | 2.4K | — | — | 242.4K | 1.00% | ↗ |
| 10 | 2001 | Judith A. Vitale CFO | 155.0K | — | — | 10.8K | — | 2.0K | 167.7K | 6.41% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Adam Wilks | Advisor | — | male |
| Ambadas Kshirsagar | Vice President of Technology | — | male |
| Bert Richards | Advisor | — | — |
| Gaynell Rogers | Advisor | — | — |
| James W. Zimbler | President, CEO, CFO, Principal Accounting Officer, Secretary & Director | — | male |
| Nick Allen Miniello | Co-Founder & Former Vice President of Sales | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for KOAN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
